Abstract
Serotonin receptor 3 (5-HT3R) antagonists have shown promise as a treatment for cognitive and early auditory processing deficits in schizophrenia. CVN058, a novel, brain-penetrant, highly potent and selective 5-HT3R antagonist, showed efficacy in rodent models of cognition and was safe and well-tolerated in Phase-1 studies.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
